Chemical genomics strategy for the discovery of new anticancer agents.
Chemical genomics represents a cooperation of biology and chemistry to identify and intervene the biological targets. Small molecules with diverse structural characteristics should be used to validate the target through interfering with the biological processes. Because of the limitation of existing chemical libraries, the diversity can be exploited using both the molecular design techniques; structure-based design and ligand-based design. These methods can guide the selection of small molecules with optimal binding properties to desired biological targets. Studies of potential molecular targets for novel anticancer drug discovery including in silico screening, QSAR, and de novo design demonstrated the importance of chemical genomics strategy to find the chemical probes and drug lead compounds.
Jung
Mankil
M
Department of Chemistry, Yonsei University, Seoul 120-749, Korea. mjung@yonsei.ac.kr
Kim
Hanjo
H
Kim
Myosun
M
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000627:therapeutic use; D015195:Drug Design; D023281:Genomics; D006801:Humans; D008024:Ligands; D008958:Models, Molecular; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics; D021281:Quantitative Structure-Activity Relationship
D000970:Antineoplastic Agents; D008024:Ligands